Biologix Hair Inc.
OTCBB : BLGX
OTCQB : BLGX

Biologix Hair Inc.

October 08, 2013 12:56 ET

Biologix Hair Inc. Announces Appointment of Mark Maybank as Chairman, Dr. Delon Human as Director

TORONTO, ONTARIO--(Marketwired - Oct. 8, 2013) - Biologix Hair Inc. (OTCBB:BLGX)(OTCQB:BLGX) has announced the appointment of Mark Maybank as chairman of the company's board of directors effective immediately. Mr. Maybank has served as a director since May 17, 2013 and steps in as chairman, replacing Ron Holland who will remain as a director as well as president of Biologix Hair (Canada) Inc.

Mark Maybank is an active investor, director and advisor. He is currently Chairman of Fleet Canada Inc., a Canadian aerospace company. He was recently the Chief Operating Officer and Director of Canaccord Financial Inc. and President and COO of Canaccord Genuity Corp. Mr. Maybank also served in various other capacities with Canaccord companies including Deputy Global Head of Capital Markets, Director of Canaccord's US and UK regulated subsidiaries and Executive VP, Managing Director, and Global Head of Research.

Previously, he was the COO and Executive VP, Business Development of Itemus Inc, an Internet and ecommerce company. Mr. Maybank currently serves as Co-Chair of Gold Medal Plates, is a member of the corporate advisory board of the Art Gallery of Ontario and is active on a number of other corporate boards.

Mr. Maybank holds his Chartered Accountant and Chartered Business Valuator designations. He earned a Bachelor of Commerce degree from the University of Alberta.

In addition, Biologix is pleased to announce Dr. Delon Human has agreed to serve as a director, effective immediately. Delon Human, M.B.Ch.B., M.Prax.Med, MFGP, DCH, MBA is the President and CEO of HEALTHDiplomats. Currently he is also the Secretary-General of the International Food and Beverage Alliance (IFBA), an alliance of the top food companies in the world. He is a published author, international lecturer and well-respected health care consultant specializing in health system and product development, corporate and product transformation, strategy formulation and health communication. He has acted as adviser to the WHO Director-General and UN Secretary-General Ban Ki Moon.

He is the immediate Past Secretary General of the World Medical Association (WMA), the global representative body for physicians. He was instrumental in the establishment of the World Health Professions Alliance, an alliance of the global representative bodies of physicians, nurses, pharmacists, dentists and physical therapists. During 2006 he was elected to serve as the Secretary-General of the Africa Medical Association (AfMA). He is a fellow of the Russian and Romanian Academies of Medical Sciences.

He qualified as physician in South Africa and completed his postgraduate studies in family medicine and child health in South Africa and Oxford, England. He was a clinician for two decades, part of the pediatric endocrinology research unit at the John Radcliffe Hospital and involved in the establishment of several medical centres, a hospital and emergency clinic in South Africa. His business studies (MBA) were completed at the Edinburgh Business School.

Biologix CEO Dr. Michael Stocker stated: "We appreciate the willingness of Dr. Human to serve on the Biologix board of directors and of Mr. Maybank to step in and fill the role of Chairman at this time. We are also grateful to Mr. Ron Holland for his able leadership as chairman during his tenure in that position and are very happy he will remain a member of the board as a director going forward."

About Biologix Hair Inc. and Biologix Hair Science Ltd.

Biologix Hair Inc. (Biologix Hair), together with its wholly owned biotechnology subsidiary, Biologix Hair Science Ltd. ™ (BHS), is focused on realizing the full market potential for its patent-pending hair loss prevention and regeneration treatment - the Biologix Hair Therapy System™ - and its demonstrated ability to prevent and reverse the effects of alopecia, which plagues hundreds of millions worldwide.

Between mid-2004 and late 2011, more than 30,000 pre-clinical-trial treatments of Biologix Revive - the essence of the Biologix Hair Therapy System™ - were administered to 5,000-plus patients in South America suffering with varying degrees of alopecia, as well as people seeking preventive treatment. The participating treatment clinicians subjectively observed and reported that virtually 100% of preventive care clients continued to retain their healthy hair and an estimated 80-85% of the males and 90-plus% of the females treated for hair regeneration experienced significant regrowth of their own natural hair. And among alopecia areata patients, virtually total hair regrowth was observed in 100% of the cases. To date, no negative side effects have been reported.

BHS is currently focused on obtaining FDA approval for its breakthrough hair loss prevention and regeneration therapy and has initiated a research and development program with one of the world's leading medical research universities, the Beijing Institute of Technology (BIT). The R&D program is an important final step before formal clinical trials and the FDA approval process begins.

Additionally, on May 11, 2012, Venable LLP, the Washington-based law firm overseeing the worldwide IP and regulatory approval processes on behalf of BHS, filed a Patent Cooperation Treaty (PCT) application on behalf of BHS for Biologix Revive in Geneva, Switzerland. The PCT is an international treaty, administered by the World Intellectual Property Organization (WIPO), to which 147 countries have as of now contracted, including Canada and the United States.

Biologix management is determined to be in a ready position to capitalize on the high-margin sales potential of the Biologix Hair Therapy System™ and is rapidly developing a global distribution network of licensed clinicians and medical practitioners seeking to become Certified Biologix Hair Therapists™ and secure exclusive territorial purchasing and treatment rights for the Biologix Hair Therapy System™.

Although the Biologix Hair Therapy System™ is currently not able to be offered in more heavily regulated markets, such as the United States, Canada and the European Union, there are countries and regions with less restrictive regulatory barriers that enable Biologix to provide immediate treatment via its clinician network while simultaneously focusing on obtaining regulatory approvals for all markets, worldwide.

BHS is in the process of evaluating where best to open a prototype commercial hair therapy treatment and medical training center in South America. Additionally, management is currently working together with its Medical Advisory Board and its team of legal advisors to determine in which strategic locations around the world to begin offering commercial treatment options upon completion of the formula standardization process.

To learn more about Clinician Licensing opportunities, Click Here or call toll free +1 855.737.0333 or +1 647.344.5900.

Disclaimer

This announcement is not an offer to sell any Biologix Hair Inc. ("Biologix") securities. Offers for any given security are made only through applicable offering circulars and related documents filed with the SEC pursuant to the Securities Act of 1933 or the Securities Exchange Act of 1934. Certain statements contained herein and subsequent oral statements made by and on behalf of Biologix may contain "forward-looking statements". Such forward-looking statements are identified by words such as "intends," "anticipates," "believes," "expects" and "hopes" and includes, without limitation, the development of treatment centers and approval from regulatory authorities as well as the ability for Biologix to obtain adequate financing to meet its business objectives. Forward-looking statements express our expectations or predictions of future events or results. They are not guarantees and are subject to many risks and uncertainties. There are a number of factors beyond our control that could cause actual events or results to be significantly different from those described in the forward-looking statements. Any or all of our forward-looking statements in this report or in any other public statements we make may turn out to be wrong. We undertake no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise. In Canada, Europe and the United States, the Biologix treatment is not approved for use by Health Canada, EMA or the FDA. The company makes no representations that it will receive Health Canada, EMA or FDA approvals.

Contact Information